News & Insights

Inherited bleeding disorders (iBDs), such as haemophilia A and B, von Willebrand disease (VWD), and Glanzmann thrombasthenia, present unique challenges for health technology assessment (HTA). Treatments are often lifelong, costly, and evolving rapidly, especially with the advent of gene therapies and non-factor replacement options like emicizumab. Economic evaluations (EEs) are essential to guide reimbursement and policy decisions, and modelling plays a central role in these

Patient Reported Outcomes in understanding lived experiences of individuals with a health condition.

Patient-Generated Data and Preferences in Europe's evolving HTA landscape.

In the rapidly evolving landscape of healthcare, patient-centricity is more than just a buzzword—it's becoming the cornerstone of...

The U.S. Food and Drug Administration (FDA) is setting a new standard for patient-centred care with its recently updated draft guidance...

Sickle cell disease (SCD) is a devasting genetic disorder. This article looks at the economic impact of SCD in Sub-Saharan Africa.

How to elicit the preferences of the patients. Patient preferences play a vital role in healthcare decision-making, especially in the...

Overview of the NICE Real World Evidence (RWE) Framework.

Integrating primary and secondary HEOR research to enhance outcomes.